|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||66.08 - 68.85|
|52 Week Range||39.30 - 75.40|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||66.31|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||508.91|
Eurofins Viracor, a leading infectious disease testing laboratory for more than 35 years, announces the launch of several combined tests which detect COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The combined SARS-CoV-2 Plus Flu A/B and RSV tests are intended for the qualitative detection of SARS-CoV-2 and the quantitative detection of Influenza A, Influenza B, and RSV.
Transplant Genomics, Inc. ("TGI") a member of Eurofins Transplant Diagnostics, is excited to introduce TruGraf Liver, the only non-invasive blood-based test to assist in lowering immunosuppression in liver transplant patients, at The Liver Meeting Digital Experience ("The Liver Meeting"). The Liver Meeting is the annual meeting of the American Association for the Study of Liver Diseases, being held online November 13-16, 2020. In continuation of Eurofins Transplant's commitment to improving organ transplant outcomes worldwide, TruGraf Liver follows TruGraf®, the only non-invasive kidney rejection test reimbursed by CMS for the surveillance of "silent" sub-clinical acute rejection in patients with stable renal function.
Eurofins CDMO announces the strategic expansion of its existing Drug Product operation capabilities with the early 2020 completion of its new Drug Product development and cGMP manufacturing facility, located in Mississauga, Canada.